Genmab A (GMAB) Income from Non-Controlling Interests (2026)
Genmab A (GMAB) posted Income from Non-Controlling Interests of -$1.0 million for Q1 2026.
Genmab A (GMAB) Income from Non-Controlling Interests (2026) Analysis & Trends
Genmab A's Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at -$1.0 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Genmab A | 1.88 Bn | 361.09 Mn | 831.00 Mn | -1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.00 Mn |